ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.

Quote:

Search for Ticker

Free Membership

Search:

DVAX: Dynavax Technologies Cp - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

DYNAVAX TECHNOLOGIES CP (NASD)
DVAX	1.26	-0.03	(-2.33%)	Vol. 167,611	15:59 ET

Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.

General Information

DYNAVAX TECH CP

2929 Seventh Street Suite 100 Berkeley, CA 94710-2753 Phone: 510 848-5100 Fax: 510 848-1327 Web: www.dynavax.com Email: None

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	03/08/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	1.29
52 Week High	3.35
52 Week Low	0.16
Beta	3.27
20 Day Moving Average	487,370.84
Target Price Consensus	2.45

% Price Change
4 Week	-9.35
12 Week	-22.70
YTD	50.00

% Price Change Relative to S&P 500
4 Week	-10.33
12 Week	-27.12
YTD	24.14

Share Information
Shares Outstanding (millions)	39.99
Market Capitalization (millions)	50.39
Short Ratio	1.25
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.23
Current Year EPS Consensus Estimate	-0.24
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	03/08/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	3.00
30 Days Ago	3.00
60 Days Ago	3.00
90 Days Ago	3.00

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	18.00
PEG Ratio	-

EPS Growth
vs. Previous Year	-71.43%
vs. Previous Quarter	-340.00%

Sales Growth
vs. Previous Year	-67.25%
vs. Previous Quarter:	-81.74%

Price Ratios
Price/Book	2.88
Price/Cash Flow	-
Price / Sales	1.01

ROE
09/30/09	14.76
06/30/09	40.36
03/31/09	-22.95

ROA
09/30/09	3.74
06/30/09	8.47
03/31/09	-3.74

Current Ratio
09/30/09	4.28
06/30/09	4.88
03/31/09	2.70

Quick Ratio
09/30/09	4.28
06/30/09	4.88
03/31/09	2.70

Operating Margin
09/30/09	5.60
06/30/09	12.30
03/31/09	-6.58

Net Margin
09/30/09	8.73
06/30/09	14.17
03/31/09	-5.47

Pre-Tax Margin
09/30/09	8.73
06/30/09	14.17
03/31/09	-5.47

Book Value
09/30/09	0.44
06/30/09	0.62
03/31/09	0.51

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	0.86
06/30/09	0.61
03/31/09	0.74

Debt to Capital
09/30/09	46.13
06/30/09	37.88
03/31/09	42.42


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research